JW (Cayman) Therapeutics Co. Ltd (JNY.F)

0,2580 -0,0140 (-5,15%) Ab 09:59AM CEST. Markt geöffnet.

JW (Cayman) Therapeutics Co. Ltd

Building B
5th Floor No. 699 Zhong Ke Road Pudong New District
Shanghai
China
86 21 5078 3699
https://www.jwtherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 398

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Yiping Li M.D.	Co-founder, Executive Chairman of the Board & CEO	782,38k	N/A	1964
Cao Xiaoping Ph.D.	Senior Vice President of Tech Operations	N/A	N/A	N/A
Dr. Shaun Paul Cordoba Ph.D.	Senior VP & Chief Scientific Officer	N/A	N/A	1980
Mr. Raymond J. Hage Jr.	Senior Vice President of Corporate Development	N/A	N/A	1968
Mr. Mark J. Gilbert M.D.	Senior Advisor & Acting Chief Medical Officer	N/A	N/A	N/A
Mr. Qiang Ma	Senior VP & Chief Commercial Officer	N/A	N/A	1978
Ms. Yun Qin	Senior Vice President of Clinical Sciences & Medical Services	N/A	N/A	1982
Dr. Su Yang	Senior Vice President Of Clinical Research & PMO	N/A	N/A	1979
Ms. Ka Man Ng A.C.I.S., A.C.S.	Company Secretary	N/A	N/A	1978

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

Corporate Governance

JW (Cayman) Therapeutics Co. Ltds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.